CASICASI Pharmaceuticals Inc (NASDAQ:CASI) Historically, October is always a great month for a trend reversal on this name. I think we could see a strong reversal over the coming wks.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.02 USD
−26.94 M USD
33.88 M USD
3.97 M
About CASI Pharmaceuticals, Inc.
Sector
CEO
Wei Wu He
Headquarters
Beijing
Website
Founded
1991
FIGI
BBG01DSTT3T7
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.
CASICASI Pharmaceuticals, Inc. (CASI) is still in bottoming mode. The technical indicators are looking better now for the stock. The MACD is starting to rise, confirming a bullish divergence has taken form and the Stochastic also has a bullish crossover. It might attempt to breakout above the $1.25 leve
CASICASI Pharmaceuticals Inc (NASDAQ:CASI) The daily chart is shaping up and I expect the next point of resistance to be at $2.25. At some point CASI will take off and never look back. I think that day will come soon and those buying at these prices will be thanking me down the road. Oppenheimer analyst
$CASI is gonna fall todayPupm&Dump trading strategy idea.
$CASI is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $1,67;
stop-loss — $1,84;
take-profit — $1,32/MOC
Do not view
CASIThursday's earnings report news has lit a fire under CASI Pharmaceuticals (NASDAQ: CASI) and I don't think it will be put out anytime soon. This looks like the start of a prolonged rally, one that could see this stock trading +400% higher than current levels according to Oppenheimer analyst Leland G
CASI - Long SetupStrong buying from COB/CEO in March at $2.06 and strong buying last year as well from same insider. Break 1.78, Stop signal 1.47. First target 2.33, Second target Momentum.
CASICASI Pharmaceuticals Inc (NASDAQ:CASI) moved up about 9.22% on strong volume last week and it looks like a lot of traders booked gains from the upwards run, but I did exactly the opposite. With the resistance level already identified on the charts and with the huge insider activity revealed, I used
$CASI KST Buy Signal CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CASI is 6.14 USD — it has increased by 2.08% in the past 24 hours. Watch CASI Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CASI Pharmaceuticals, Inc. stocks are traded under the ticker CASI.
CASI stock has fallen by −2.00% compared to the previous week, the month change is a 12.36% rise, over the last year CASI Pharmaceuticals, Inc. has showed a 27.06% increase.
CASI reached its all-time high on Mar 1, 2000 with the price of 11,137.50 USD, and its all-time low was 1.45 USD and was reached on Dec 27, 2022. View more price dynamics on CASI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CASI stock is 8.48% volatile and has beta coefficient of 1.00. Track CASI Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is CASI Pharmaceuticals, Inc. there?
Today CASI Pharmaceuticals, Inc. has the market capitalization of 82.22 M, it has increased by 4.97% over the last week.
Yes, you can track CASI Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
CASI Pharmaceuticals, Inc. is going to release the next earnings report on Nov 14, 2024. Keep track of upcoming events with our Earnings Calendar.
CASI earnings for the last quarter are −0.52 USD per share, whereas the estimation was −0.63 USD resulting in a 17.46% surprise. The estimated earnings for the next quarter are −0.62 USD per share. See more details about CASI Pharmaceuticals, Inc. earnings.
CASI Pharmaceuticals, Inc. revenue for the last quarter amounts to 3.98 M USD, despite the estimated figure of 4.43 M USD. In the next quarter, revenue is expected to reach 4.56 M USD.
CASI net income for the last quarter is −6.96 M USD, while the quarter before that showed −9.53 M USD of net income which accounts for 26.90% change. Track more CASI Pharmaceuticals, Inc. financial stats to get the full picture.
No, CASI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 243.00 employees. See our rating of the largest employees — is CASI Pharmaceuticals, Inc. on this list?
Like other stocks, CASI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CASI Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CASI Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CASI Pharmaceuticals, Inc. stock shows the neutral signal. See more of CASI Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.